首页> 外文会议>Conference on biochemical and molecular engineering >ENCAPSULATION BIOPROCESSES FOR DIABETES CELLULAR THERAPY
【24h】

ENCAPSULATION BIOPROCESSES FOR DIABETES CELLULAR THERAPY

机译:糖尿病细胞治疗的胶囊化生物过程

获取原文

摘要

The number of cell and gene therapy products approved in North America now exceeds 15, creating a need for bioprocesses tailored to this type of biologics. The Stem Cell Bioprocessing Laboratory at McGill, led by Dr. Hoesli, Canada Research Chair in Cellular Therapy Bioprocess Engineering, is developing new materials and methods to produce and deliver promising cell-based products - in particular for the treatment of diabetes and cardiovascular disease. Type 1 diabetes is an autoimmune disease leading to the loss of the insulin-producing beta cells of the pancreas. Islet transplantation aims to replace these insulin producing cells rather than replacing the missing insulin hormone. Over 85% of islet transplant recipients can live without insulin injections for at least 1 year, with some patients remaining insulin-independent for over 5 years. Access to this promising long-term treatment to diabetes is limited by donor islet supply as well as the risks associated with lifelong immunosuppression following this intervention. We and others are developing scalable bioprocesses to generate pancreatic cells from pluripotent stem cells, to purify the cells of interest, and to transplant them while circumventing the need for immunosuppression. This presentation will review upstream processing, downstream processing and formulation/delivery methods related to this challenging cell-based product. Examples of novel bioprocesses for pluripotent stem cell differentiation and pancreatic cell encapsulation in immunoprotective devices will be presented. Avenues for future research and development include engineering devices that maximize cell oxygenation and survival while also allowing graft retrieval or replacement. One of these approaches is the engineering of vascularized tissue constructs using 3D printing. As the cell therapy field continues to evolve and mature, complex combination products including therapeutic cells, biomaterials as well as drugs are expected to emerge on the market.
机译:目前,在北美获得批准的细胞和基因治疗产品的数量已超过15种,因此需要针对此类生物制剂的生物过程。 McGill的干细胞生物加工实验室由加拿大细胞疗法生物过程工程研究主席Hoesli博士领导,正在开发新的材料和方法来生产和提供有前途的细胞基产品,特别是用于治疗糖尿病和心血管疾病的产品。 1型糖尿病是一种自身免疫性疾病,会导致胰腺产生胰岛素的β细胞丢失。胰岛移植旨在替代这些产生胰岛素的细胞,而不是替代缺失的胰岛素激素。超过85%的胰岛移植接受者可以不注射胰岛素而生存至少1年,其中一些患者在5年内仍不依赖胰岛素​​。捐献者胰岛的供应以及这种干预后与终身免疫抑制相关的风险限制了获得这种有希望的糖尿病长期治疗的机会。我们和其他人正在开发可扩展的生物过程,以从多能干细胞中产生胰腺细胞,纯化目标细胞,并在避免免疫抑制的同时进行移植。本演讲将回顾与这种具有挑战性的基于细胞的产品有关的上游加工,下游加工以及配方/递送方法。将提供用于免疫保护装置中的多能干细胞分化和胰腺细胞封装的新型生物过程的例子。未来研究和开发的途径包括使细胞氧合和存活最大化的工程设备,同时还允许进行移植物取回或替换。这些方法之一是使用3D打印对血管化组织构建体进行工程设计。随着细胞治疗领域的不断发展和成熟,包括治疗细胞,生物材料和药物在内的复杂组合产品有望在市场上出现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号